tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SONN Stock Latest News

Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
Company AnnouncementsSonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
1d ago
8K
SONN
Sonnet BioTherapeutics reports data from Phase 1b/2a trial of SON-080
PremiumThe Fly
Sonnet BioTherapeutics reports data from Phase 1b/2a trial of SON-080
1d ago
SONN
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
PremiumPress Releases
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
1d ago
SONN
Sonnet BioTherapeutics files to sell 5.77M shares of common stock for holders
PremiumThe Fly
Sonnet BioTherapeutics files to sell 5.77M shares of common stock for holders
20d ago
SONN
Sonnet BioTherapeutics announces exercise of warrants for $3.4M in proceeds
PremiumThe Fly
Sonnet BioTherapeutics announces exercise of warrants for $3.4M in proceeds
1M ago
SONN
Sonnet BioTherapeutics Unveils Innovative Immunotherapeutic Candidates
PremiumCompany AnnouncementsSonnet BioTherapeutics Unveils Innovative Immunotherapeutic Candidates
1M ago
8K
SONN
Sonnet BioTherapeutics announces generation of two drug candidates
PremiumThe Fly
Sonnet BioTherapeutics announces generation of two drug candidates
1M ago
SONN
Sonnet BioTherapeutics to present SB221 as trial in progress at ASCO 2024
PremiumThe Fly
Sonnet BioTherapeutics to present SB221 as trial in progress at ASCO 2024
2M ago
SONN
Sonnet BioTherapeutics announces review of strategic alternatives
PremiumThe Fly
Sonnet BioTherapeutics announces review of strategic alternatives
2M ago
SONN
Sonnet BioTherapeutics announces updated clinical data for SON-1010
PremiumThe Fly
Sonnet BioTherapeutics announces updated clinical data for SON-1010
2M ago
SONN
Sonnet BioTherapeutics price target lowered to $7 from $11 at EF Hutton
PremiumThe Fly
Sonnet BioTherapeutics price target lowered to $7 from $11 at EF Hutton
2M ago
SONN
Sonnet Biotherapeutics Holdings, Inc. (SONN) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Sonnet Biotherapeutics Holdings, Inc. (SONN) Q2 Earnings Cheat Sheet
3M ago
SONN
Sonnet BioTherapeutics files to sell 5M shares of common stock for holders
PremiumThe FlySonnet BioTherapeutics files to sell 5M shares of common stock for holders
3M ago
SONN
Sonnet BioTherapeutics announces safety data from Phase 1b/2a trial of SON-080
PremiumThe Fly
Sonnet BioTherapeutics announces safety data from Phase 1b/2a trial of SON-080
5M ago
SONN
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
PremiumCompany Announcements
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
5M ago
8K
SONN
Sonnet BioTherapeutics price target lowered to $30 from $75 at Chardan
PremiumThe Fly
Sonnet BioTherapeutics price target lowered to $30 from $75 at Chardan
5M ago
SONN
Sonnet BioTherapeutics reports Q1 EPS (31c) vs. ($17.62) last year
PremiumThe Fly
Sonnet BioTherapeutics reports Q1 EPS (31c) vs. ($17.62) last year
5M ago
SONN
SONN Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SONN Earnings this Week: How Will it Perform?
6M ago
SONN
Sonnet BioTherapeutics Regains Compliance, Risks Nasdaq Delisting
PremiumCompany Announcements
Sonnet BioTherapeutics Regains Compliance, Risks Nasdaq Delisting
6M ago
8K
SONN
Sonnet BioTherapeutics Navigates Financial Compliance Hurdles
PremiumCompany AnnouncementsSonnet BioTherapeutics Navigates Financial Compliance Hurdles
6M ago
8K
SONN
Sonnet BioTherapeutics files $100M mixed securities shelf
PremiumThe Fly
Sonnet BioTherapeutics files $100M mixed securities shelf
7M ago
SONN
Sonnet BioTherapeutics announces publication of preclinical data on SON-1210
PremiumThe Fly
Sonnet BioTherapeutics announces publication of preclinical data on SON-1210
7M ago
SONN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >